1 Diagnostic accuracy of two commercial SARS-CoV-2 Antigen-detecting rapid tests at the

2 point of care in community-based testing centers

3

| 4 | Alice Berger ^{1*} , Marie Therese Ngo Nsoga ^{1*} , Francisco Javier Perez-Rodriguez ^{2*} , Yasmine Abi |
|----|--|
| 5 | Aad ¹ , Pascale Sattonnet-Roche ² , Angèle Gayet-Ageron ³ , Cyril Jaksic ³ , Giulia Torriani ⁴ , Erik |
| 6 | Boehm ¹ , Ilona Kronig ¹ , Jilian A. Sacks ⁵ , Margaretha de Vos ⁵ , Frédérique Jacquerioz Bausch ⁶ , |
| 7 | François Chappuis ⁶ , Laurent Kaiser ^{1,2,7} , Manuel Schibler ^{1,2,7} , Isabella Eckerle ^{1, 2,7} for the Geneva |
| 8 | Centre for Emerging Viral Diseases |
| 9 | |
| 10 | ¹ Division of Infectious Disease, Geneva University Hospitals, Geneva, Switzerland. |
| 11 | ² Geneva Centre for Emerging Viral Diseases, Geneva University Hospitals, Geneva, |
| 12 | Switzerland. |
| 13 | ³ CRC & Division of Clinical-Epidemiology, Department of Health and Community Medicine, |
| 14 | University of Geneva & University Hospitals of Geneva |
| 15 | ⁴ Department of Microbiology and Molecular Medicine, University of Geneva, Geneva, |
| 16 | Switzerland |
| 17 | ⁵ Foundation for Innovative New Diagnostics, Geneva, Switzerland |
| 18 | ⁶ Department of Primary Care, Geneva University Hospitals, Geneva, Switzerland. |
| 19 | ⁷ Laboratory of Virology, Division of Laboratory Medicine, Geneva University Hospitals, |
| 20 | Geneva, Switzerland |
| 21 | |
| 22 | *contributed equally |
| 23 | |

24 NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

- 25 Corresponding author:
- 26 Isabella Eckerle
- 27 University Hospital of Geneva
- 28 Rue Gabrielle-Perret-Gentil 4
- 29 CH-1205 Geneva
- 30 Phone: +41 22 37 29820 / +41 79 55 33 895
- 31 Fax: +41 22 37 24097

32 Abstract

Background. Antigen-detecting rapid diagnostic tests for SARS-CoV-2 offer new opportunities
 for the quick and laboratory-independent identification of infected individuals for control of
 the SARS-CoV-2 pandemic.

36 Methods. We performed a prospective, single-center, point of care validation of two antigen-37 detecting rapid diagnostic tests (Ag-RDT) in comparison to RT-PCR on nasopharyngeal swabs. 38 Findings. Between October 9th and 23rd, 2020, 1064 participants were enrolled. The Panbio[™] 39 Covid-19 Ag Rapid Test device (Abbott) was validated in 535 participants, with 106 positive 40 Ag-RDT results out of 124 positive RT-PCR individuals, yielding a sensitivity of 85.5% (95% CI: 41 78.0–91.2). Specificity was 100.0% (95% CI: 99.1–100) in 411 RT-PCR negative individuals. The 42 Standard Q Ag-RDT (SD Biosensor, Roche) was validated in 529 participants, with 170 positive 43 Ag-RDT results out of 191 positive RT-PCR individuals, yielding a sensitivity of 89.0% (95%CI: 44 83.7–93.1). One false positive result was obtained in 338 RT-PCR negative individuals, yielding 45 a specificity of 99.7% (95%CI: 98.4–100). For individuals presenting with fever 1-5 days post 46 symptom onset, combined Ag-RDT sensitivity was above 95%.

Interpretation. We provide an independent validation of two widely available commercial Ag-RDTs, both meeting WHO criteria of \geq 80% sensitivity and \geq 97% specificity. Although less sensitive than RT-PCR, these assays could be beneficial due to their rapid results, ease of use, and independence from existing laboratory structures. Testing criteria focusing on patients with typical symptoms in their early symptomatic period onset could further increase diagnostic value.

Funding. Foundation of Innovative Diagnostics (FIND), Fondation privée des HUG, Pictet
 Charitable Foundation.

55 Introduction

56 The 2019 novel coronavirus (SARS-CoV-2) which causes Coronavirus Disease 19 (COVID-19), 57 has led to an unprecedented pandemic and a global public health crisis. Developing diagnostic 58 strategies that are easily accessible, provide rapid results and are of low cost to allow use in 59 resource limited settings is critical in order to control the pandemic. While RT-PCR based 60 detection remains the standard for the detection of emerging respiratory viruses (1,2), the 61 global need for virus detection methods has fueled research and development of diagnostic 62 tests, including as Antigen-detecting rapid diagnostic tests (Ag-RDT), that can be performed at 63 the point of care (POC) (3).

64 Such laboratory-independent tests could be key to detecting acutely infected and especially 65 contagious individuals, allowing for control of the pandemic by quickly isolating individuals 66 during their contagious period to prevent further transmission. These tests can also help 67 overcome bottlenecks such as overwhelmed diagnostic laboratories and global shortages of 68 PCR reagents, while being affordable (4). Ag-RDTs could enable mass screenings, which allow 69 estimation of active infection prevalence, and confirming a COVID-19 diagnosis especially in 70 settings where results are not available in a timely manner (5). Given that viral load, as 71 measured by RNA levels, peaks near symptom onset (6–8) and contagiousness can begin days 72 before symptom onset (9,10), it is expected that RDTs would have the highest sensitivity (SN) 73 in those infected individuals that are most contagious. However, reported SNs of Ag-RDTs vary 74 widely, and manufacturer reported SNs are often substantially higher than the SNs reported 75 by independent assessments (11). The World Health Organisation (WHO) has published an Ag-76 RDT target product profile, aiming at SN \geq 80% and a specificity (SP) of \geq 97% (5,12). Thus, we 77 sought to evaluate the performance of two commercially available Ag-RDTs through a

- 78 prospective, single-center POC validation in comparison to RT-PCR for detecting SARS-CoV-2
- vsing nasopharyngeal swabs (NPS) under real-life conditions.
- 80
- 81 Methods
- 82 Ethics

The study was approved by the Cantonal ethics committee (Nr. 2020-02323). All study
 participants and/or their legal guardians provided written informed consent.

- 85
- 86 Setting

The study was performed in two geographically different testing centres in Geneva, run by our institution, the Geneva University Hospitals: one adjacent to the University hospital ("Sector E") and the other located in another part of the city ("Sector G") between October 9th and October 23rd, 2020. Both centres are supervised by the same team, and did not differ in their infrastructure, so we analyzed them as a single centre study.

92

93 Study design and participants

94 The primary objective of this prospective study was to assess the diagnostic accuracy (SN and 95 SP) of the Ag-RDTs compared to the reference RT-PCR. All individuals presenting to the testing 96 centres were informed about the study and enrolled if they consented. Participants were ≥16 97 years of age, with suspected SARS-CoV-2 infection according to the local governmental testing 98 criteria. This included suggestive symptoms for COVID-19 and/or recent exposure to a SARS-99 CoV-2 positive person. Asymptomatic individuals were included if they were notified by the 100 Swiss COVID-19 app about a contact offering the option to get tested on day 5 after contact,

101 or if they received a notification from local health authorities (screening of people with high102 risk exposure in a cluster).

103

104 *Study procedures*

For each participant, two NPS were collected. The first was a standard flocked swab placed in viral transport media (VTM), used routinely for viral genome detection by RT-PCR. The second NPS, provided in the Ag-RDT kit, was obtained from the contralateral nostril and was performed as recommended by the manufacturer. Both swabs were taken by the same trained nurse. All Ag-RDTs were performed immediately at the sample collection site. Adequate personal protective equipment was used while collecting the NPSs and performing the RDTs.

112

113 Data collection

114 Clinical data were collected for each patient upon presentation with a questionnaire including 115 the number of days post symptom onset (DPOS), known contact to a previous SARS-CoV-2 116 infected person, comorbidities and type of symptoms. The following symptoms were 117 recorded: rhinorrhea (runny nose), odynophagia, myalgia, chills, dry cough, productive cough, 118 red expectoration, fever (anamnestic), anosmia/ageusia (loss of smell or taste), 119 gastrointestinal symptoms, asthenia, dyspnea, thoracic pain and headache.

Comorbidities included in the questionnaire were hypertension, cardiovascular disease, chronic pulmonary disease, diabetes, chronic renal failure, active cancer including lymphoproliferative disease, severe immunosuppression, immunosuppressive therapy, pregnancy, and obesity (BMI >40 kg/m²).

124

125 Ag-RDT testing

The two validated Ag-RDTs were Panbio Covid-19 Ag Rapid Test device (Abbott Rapid Diagnostics) and Standard Q (SD Biosensor, Roche). Both Ag-RDTs were used as recommended by the manufacturers, using only materials provided by the manufacturers in the kits. Both assays were manually read, with two individuals reading the results separately after the indicated time. In case of discordant results, the two validators sought a consensus. All visible bands were considered a positive result. All Ag-RDT results were photographically documented.

133

134 RT-PCR testing

All participants were tested by a dual target RT-PCR assay for SARS-CoV-2 (Cobas, Roche) using NPS in 3mL VTM. For further analysis, only cycle threshold (Ct) values for the E-gene were used. For calculation of viral loads (VL) as SARS-CoV-2 genome copy numbers per mL, a standard curve was obtained by using a quantified supernatant from a cell culture isolate of SARS-CoV-2. All VLs were calculated from the Ct-values, according to log10 SARS-CoV-2 RNA copies/ml = (Ct-44.5)/-3.3372 for Cobas (13,14).

141

142 Statistics

We enrolled all patients who met the SARS-CoV-2 testing criteria, over a 2-week period. During the first and second week, 529 and 535 patients were enrolled respectively. The target sample size was 530, as it would have sufficient power to generate a 95% confidence interval (CI) with a lower bound above the WHO target of 80%, if the prevalence was 25% and the measured SP was ≥87.5%.

All continuous variables were presented by their mean ±standard deviation (SD) and median (interquartile range, IQR), categorical variables were presented by their frequencies and relative proportions. For comparisons of continuous variables, we used a nonparametric Mann-Whitney test due to small sizes; for comparisons of categorical variables, we either performed Chi² or Fischer's exact tests, depending on applicability.

To enable Ag-RDT result combination, we performed a Bayesian t-test on their sensitivities and specificities. To be able to conduct the t-test, the confidence intervals of both sensitivities and specificities were converted into standard deviation to allow for the t-test to be conducted. The test computes a Bayesian Factor (BF) that allows comparison of the probability of observing our data under H₀ (both tests are equal in term of SN and SP) and H₁ (both tests are different). All analyses were performed using STATA version intercooled 16 (Stata Corp.,

159 College Station, TX, USA). Statistical significance was defined as p<0.05 (two-sided).

160

161 Results

162 Between October 9th and October 23rd, 2020, 1064 participants were enrolled and included in the analysis. 535 participants were tested with the Panbio Ag-RDT from October 09th to 16th 163 164 and 529 participants were tested with the Standard Q Ag-RDT from October 19th to 23rd, 2020. 165 The demographic and clinical characteristics of the study population are shown in **Table 1**. The 166 mean age of the study participants was 34.9 years (SD ±10.9) with 53.8% being female. The 167 mean DPOS to testing was 2.7 (SD ±1day). Overall, 29.6% of participants were positive by RT-168 PCR with a mean Ct-value of 22.5 (SD ±5.1), corresponding to a VL of 1.8E7 SARS-CoV-2 169 copies/mL. Most patients (97.8%) were symptomatic upon presentation at the testing centre, 170 with only 3 reporting no symptoms. Symptoms information was missing for 4 patients. The 171 study population tested with the Standard Q vs. was younger than that tested with the Panbio

172 assay (34.9 ±10.9 vs 38.5 ±13.6 years, respectively, p<0.001) and DPOS differed slightly 173 (2.9±1.5 vs. 2.6±2.0 days, respectively, p=0.0125). Ct-values did not differ significantly between the two groups (p=0.450): 22.6 (SD ±4.9) in the Standard Q group vs. 22.4 (SD ±5.4) 174 175 in the Panbio group, corresponding to 1.7E7 and 1.9E7 SARS-CoV-2 RNA copies/mL, 176 respectively. The RT-PCR positivity rate was 23.2% and 36.1% for the population tested with 177 the Panbio and the Standard Q, respectively, corresponding to an increase in the overall PCR 178 positivity rate and reflecting the rapidly increasing local incidence during the time of this 179 study.

The overall test performance for the Standard Q was 89.0% SN (95%CI: 83.7-93.1) and 99.7%
SP (95%CI: 98.4-100%). The overall test performance for the Panbio assay was 85.5% SN
(95%CI: 78.0-91.2) and 100% SP (95%CI: 99.1-100) (Table 2).

183 Ct-values of samples with positive Ag-RDT results ranged from 14.2-34.0 and 14.4-34.2 for 184 Panbio and Standard Q (p=0.1766), respectively, while Ct-values of samples of samples tha 185 tested falsely negative by Ag-RDT ranged from 16.0-39.7 and 19.8-37.4 (p=0.7998), 186 respectively. Median Ct-values of Ag-RDT positive samples (Panbio: 20.4, IQR: 18.1-23.8; Standard Q: 21.2, IQR 18.6-24) were lower than those of Ag-RDT negative samples (Panbio: 187 188 30.5, IQR: 27-35.9; Standard Q: 30.4, IQR: 25.7-33.9) (Figure 1). Furthermore, we evaluated 189 overall Ag-RDT results in relation to Ct-values/viral load as well DPOS (Figure 2). False-negative 190 results occurred in both assay across all DPOS.

We compared SN and SP between the two Ag-RDTs and concluded that we could accept, with high probabilities, (respectively likelihood ratio of BF₀₁=10.2 and 11.9) the hypothesis of equivalent SN and SP. Based on this, a combined SN of 87.6% (95%CI: 83.5-91.0) and a combined SP of 99.9% (95%CI: 99.3-100) for both Ag-RDTs were calculated with a positive predictive value of 99.6% (95%CI: 98.0-100) and a negative predictive value of 95.0% (95%CI:

196 93.3-96.5). In order to identify subpopulations in which maximal SN could be reached with

- 197 these tests, we analyzed SN by DPOS, Ct-values as determined by RT-PCR, type of symptoms,
- 198 comorbidities, and previous contact with a confirmed SARS-CoV-2 infection.
- 199 Combined SN varied according to Ct-values: it was highest in samples with low Ct-values, with
- 200 a SN of 98.4% (95% CI: 94.2-99.8) for Ct ≤20 (≤1.0E8 SARS-CoV-2 copies/mL), decreased slightly

201 to 95.5% (95%CI: 89.9-98.5) for 20 < Ct ≤25 (<1.0E8 SARS-CoV-2 copies/mL ≤ 3.2E6), dropped

202 further to 89.9% (95%CI: 86.0-93.0) for Ct ≤35 (≤3.2 E3 SARS-CoV-2 copies/mL) and was lowest

203 (only 40.9% (95%CI: 20.7-63.6)) for 30< Ct ≤35 (<1.0E5 SARS-CoV-2 copies/mL ≤3E3) (Figure

204 **3**). The SN for all samples with a Ct value ≤26.7 (≤1E6 SARS-CoV-2 copies/mL), an assumed cut-

205 off for presence of infectious virus, was 95.7% (95%CI: 92.4-97.8).

206 SN increased with DPOS, from 88.2% at 0 DPOS (95%CI: 63.6-98.5) to 94.3% (95%CI: 84.3-98.8,

207 p=0.030) at 1 DPOS, and remained high until 5 DPOS. The highest SN was seen between 1

208 DPOS and 4-5 DPOS, ranging from 94.3% (95%CI: 84.3-98.8) to 94.8% (95%CI: 85.6-98.9), with

a decline after 5 DPOS (Figure 4A).

210 Additionally, we analyzed SN according to specific symptoms, differentiating between typical 211 COVID-19 symptoms (fever/chills, cough and anosmia/ageusia) and more non-specific 212 symptoms of respiratory infection (all other symptoms reported). The highest SN of 93.8% 213 (87.0-97.7) was observed for patients presenting with fever/chills and cough at the time of 214 testing, followed by patients presenting with anosmia/ageusia or cough and fever/chills with 215 a SN of 93.7% (95%CI: 87.4-97.4), but only 73.8% (95%CI: 58.0-86.1) in patients presenting 216 with non-specific signs (Figure 4B). No difference in SN was seen between patients with 217 (89.3%, 95%CI: 71.8-97.7, n=28) or without (87.5%, 95%CI: 83.1-91.1, n=287) comorbidities 218 (p=0.999). Typical symptoms were more frequent in patients with comorbidities (100%, 15/15 219 patients) than in patients without comorbidities (86.5%, 96/138 patients) (p=0.012), however

- 220 sample size was small. No difference was seen in patients with or without contact with a
- recently positive case (p=0.065). We further analysed by DPOS, and found that the highest SN
- was seen in patients with fever/chills and presenting between 1 and 5 DPOS, at 95.7% SN
- 223 (95%CI: 91.0-98.4).

224 **Discussion**

This study provides an independent, POC validation of two commercial Ag-RDTs in comparison
to SARS-CoV-2 RT-PCR and according to demographic and clinical information. This combined
validation of two similar assays provides performance data in a real-life high incidence test
setting with an approach aimed at an immediate implementation solution.
Both RDTs performed well with an overall SN of 87.6% (95%CI: 83.5-91) and a very high SP of

230 99.9% (95%CI: 99.3-100) in our test setting during a time of very high SARS-CoV-2 weekly 231 incidence (375/100,000 to 824/100,000 inhabitants) and a SARS-CoV-2 RT-PCR positivity rate 232 >20%. SN was higher in sub-populations with earlier DPOS numbers and characteristic COVID-233 19 symptoms. Importantly we highlight that on day 0 of symptoms, the SN may be lower than 234 during the subsequent days, and as expected, the sensitivity drops rapidly when the Ct-values 235 increase above a threshold of 30, mostly after 6-7 days. These results suggest that with 236 increasing availability, Ag-RDTs can enable rapid and reliable identification of SARS-CoV-2 237 cases and hold a promise for more efficient control of the current pandemic, independent of 238 existing diagnostic structures.

The highest VL and thus the highest SARS-CoV-2 transmission probability occurs within the 239 240 first week of symptom onset, with VLs peaking shortly before or at the time of symptom onset 241 (6). Culturable virus has been predominantly found in the first week after symptom onset, up 242 to a VL in the range of 1E6 copies/ml (14–17). This cut-off was also chosen by WHO in their 243 Ag-RDT target product profile guide for SARS-CoV-2 diagnostics (12). The SN of the Ag-RDTs 244 validated here, for patients presenting with a VL compatible with contagiousness, was 95.7%. 245 Correspondingly, the highest Ag-RDT SN was also observed at early DPOS numbers and in 246 patients with low Ct-values, again suggesting reliable identification of contagious individuals.

247 Our findings at the POC are in line with other validations performed across countries and at 248 different SARS-CoV-2 prevalence, although study designs and specimens used varied 249 considerably between studies. Standard Q was reported to have SNs between 70.6-88.7%, 250 while SP remained high throughout these studies between 97.6-100% (18–24). A clinical study 251 performed similarly to ours in a much lower-incidence setting (<1% RT-PCR positivity rate), 252 found a SN/SP of 76.6%/100%, using a mixture of NPS and combined oro- and naso-pharyngeal 253 swabs from a total of 2417 participants with 47 RT-PCR positive samples yielding 36 Ag-RDT 254 (18).

For Panbio, other studies have reported SNs ranging from 73.3-91.7% with SP in the range of 94.9-100% (25–28). Notably, the highest reported SN of 91.7%/98.9% comes from a study using 1,406 frozen archived NPS specimens of which 951 were positive by RT-PCR. However here tests were not done at the POC, and although the use of frozen samples is possible for RDTs (depending on manufacturers recommendation and on viral transport medium used), it is not their intended use (19,25). It is also unknown if a freeze-thaw cycle can affect the accessibility of viral antigens for Ag-RDT purposes.

262 While significant variation in overall SN is observed for the validated Ag-RDTs across studies, 263 there is remarkable similarity when comparing samples with Ct-values in the same range – 264 although caution must be exercised equating Ct-values to VLs across different studies. When 265 considering Ct-values of <25, the Standard Q test was reported to have a SN of 100% (18), 266 while the Panbio was reported to have a SN of 97.1% (27) or 98.2% (25), which is in agreement 267 with our results of 97%. In contrast to most other validations, we did observe some cases of 268 false-negative Ag-RDT results in patients with low Ct-values/high VLs across a range of DPOS. 269 It is likely that these patients are contagious and could transmit SARS-CoV-2, with VLs that are 270 compatible with culturable virus.

We did not find any validation of Ag-RDTs that has analyzed SN based on type of symptoms, which could be an additional factor for testing algorithms. Our data suggests that the best SN is found in symptomatic individuals with symptoms suggestive of COVID-19, early in the disease between day 1 and 5. The presence of only non-specific symptoms of respiratory illness corresponded to lower SN, however, few study participants had no COVID-19 specific symptoms at all.

277 Our study has several strengths. The Ag-RDTs were performed at the POC in parallel to RT-278 PCR, and is one of the largest in terms of RT-PCR positive individuals. The test population was 279 mainly young adults without comorbidities, who mostly had typical COVID-19 symptoms that 280 were still mild enough not to require hospitalization. This represents a population screened 281 for public health intervention, and not for diagnostic purposes in a hospital setting; and the 282 majority of SARS-CoV-2 infected individuals at the current phase of the epidemic in the 283 community, which is an important group for early identification to limit viral transmission. 284 Thus, the results of our study support implementing the Ag-RDTs in a decentralized manner 285 for community testing, which could significantly alleviate the burden on diagnostic 286 laboratories and hospital staff.

287 Although Ag-RDTs are less sensitive than RT-PCR and, in our study, false-negative Ag-RDT 288 results were also seen in patients with high VL, the public health benefit of quickly identifying 289 a large proportion of SARS-CoV-2 positive individuals in the community would still outweigh 290 the disadvantages of occasional missed diagnoses (29). Repeatedly testing and following 291 general recommendations like self-isolation for symptomatic individuals, even after a negative 292 Ag-RDT would probably largely prevent further spread from individuals who had false-293 negative results. In a high prevalence situation like ours, positive Ag-RDTs have a high positive-294 predictive value, while negative results are less reliable, and thus negative-results should not

be used for rule-out purposes or for any kind of reduced infection prevention measures. The
lower SN found at 0 DPOS was probably due to a still increasing VL. Re-testing with an Ag-RDT
or RT-PCR, in case of persisting symptoms, could overcome this limitation.

Furthermore, our validation showed very high SP, with only one false-positive Ag-RDT result in an overall sample of 315 RT-PCR positive patients. Interestingly, the patient with this putative false-positive result returned 3 days later because of persisting respiratory symptoms, and then tested positive for SARS-CoV-2 by RT-PCR.

302 During the time this study was conducted, the Canton of Geneva was experiencing a severe 303 second wave of SARS-CoV-2 infections, with a very high incidence as well as high RT-PCR 304 positivity rates, thus extrapolating the findings of our study to low prevalence settings must 305 be done with caution. Furthermore, our study population consisted mainly of young 306 symptomatic individuals in an outpatient setting, thus diagnostic performance in other groups 307 needs further validation. All diagnostic testing was performed on NPS collected by trained 308 nurses, thus the use of the test with other materials (e.g. anterior nares swabs) or in other 309 settings (e.g. self-testing) needs to be further validated, however a first study on anterior nasal 310 samples showed promising results (30). Due to logistical and ethical reasons, we were not able 311 to perform paired comparisons of both Ag-RDTs at the same time by taking three separate 312 NPS, which would have helped to control for prevalence variation and inter-cohort variability. 313 Nonetheless, we used robust methods to confirm that the SN and SP of both Ag-RDTs was 314 equivalent, and further combined results of both Ag-RDTs.

In conclusion, we show good diagnostic accuracy of both Ag-RDTs, especially for rule-in purposes of infected individuals and in testing patients with defined clinical criteria. The SN for identification of SARS-CoV-2 infected individuals during the period of highest infectiousness, the rapidity of results as well as the independence from existing laboratory

- 319 structures make these Ag-RDTs promising tools for SARS-CoV-2 infection control in the 320 community.
- 321

322 Acknowledgements

- 323 We thank all nurses and staff at the testing Centre Sectors of our institution as well as the
- 324 patients for their willingness to participate in the study. We thank Catia Machado-Delgado for
- 325 excellent technical assistance and Stéphanie Baggio for help with data analysis.
- 326

327 Funding

328 The study was supported by the Foundation for Innovative New Diagnostics, the Fondation

329 privée des HUG and Pictet Charitable Foundation. M.T. Ngo Nsoga is a beneficiary of the

- 330 excellence grant from the Swiss confederation and the grant from the humanitarian
- 331 commission of the university hospitals of Geneva.

332 References

- 333 1. Corman VM, Eckerle I, Bleicker T, Zaki A, Landt O, Eschbach-Bludau M, et al. Detection of a novel human 334 coronavirus by real-time reverse-transcription polymerase chain reaction. Eurosurveillance. 2012 Sep 335 27;17(39):20285.
- 336 2. Drosten C, Günther S, Preiser W, van der Werf S, Brodt H-R, Becker S, et al. Identification of a Novel 337 Coronavirus in Patients with Severe Acute Respiratory Syndrome. New England Journal of Medicine. 338 2003 May 15;348(20):1967-76.
- 339 3. Guglielmi G. The explosion of new coronavirus tests that could help to end the pandemic. Nature. 2020 340 Jul;583(7817):506-9.
- 341 Mina MJ, Parker R, Larremore DB. Rethinking Covid-19 Test Sensitivity — A Strategy for Containment. N 4. 342 Engl J Med. 2020 Sep 30; Epub ahead of print.
- 343 5. Antigen-detection in the diagnosis of SARS-CoV-2 infection using rapid immunoassays [Internet]. [cited 344 2020 Oct 8]. Available from: https://www.who.int/publications-detail-redirect/antigen-detection-in-the-345 diagnosis-of-sars-cov-2infection-using-rapid-immunoassays
- 346 6. He X, Lau EHY, Wu P, Deng X, Wang J, Hao X, et al. Temporal dynamics in viral shedding and 347 transmissibility of COVID-19. Nature Medicine. 2020 May;26(5):672-5.
- 348 Zou L, Ruan F, Huang M, Liang L, Huang H, Hong Z, et al. SARS-CoV-2 Viral Load in Upper Respiratory 7. 349 Specimens of Infected Patients. New England Journal of Medicine. 2020 Mar 19;382(12):1177-9.
- 350 8. Walsh KA, Jordan K, Clyne B, Rohde D, Drummond L, Byrne P, et al. SARS-CoV-2 detection, viral load and 351 infectivity over the course of an infection. J Infect. 2020 Jun 29;81(3):357-71.
- 352 9. Lauer SA, Grantz KH, Bi Q, Jones FK, Zheng Q, Meredith HR, et al. The Incubation Period of Coronavirus 353 Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application. Ann 354 Intern Med. 2020 Mar 10;172(9):577-82.
- 355 Byrne AW, McEvoy D, Collins AB, Hunt K, Casey M, Barber A, et al. Inferred duration of infectious period 10. 356 of SARS-CoV-2: rapid scoping review and analysis of available evidence for asymptomatic and 357 symptomatic COVID-19 cases. BMJ Open. 2020 Aug 5;10(8):e039856.
- 358 11. Walle IV, Leitmeyer K, Broberg EK, Group TEC-19 microbiological laboratories. Meta-analysis of the 359 clinical performance of commercial SARS-CoV-2 nucleic acid, antigen and antibody tests up to 22 August 360 2020. medRxiv. 2020 Sep 18;2020.09.16.20195917.
- 361 12. COVID-19 Target product profiles for priority diagnostics to support response to the COVID-19 pandemic 362 v.1.0 [Internet]. [cited 2020 Oct 8]. Available from: https://www.who.int/publications/m/item/covid-19-363 target-product-profiles-for-priority-diagnostics-to-support-response-to-the-covid-19-pandemic-v.0.1
- 364 13. Baggio S, L'Huillier AG, Yerly S, Bellon M, Wagner N, Rohr M, et al. SARS-CoV-2 viral load in the upper 365 respiratory tract of children and adults with early acute COVID-19. Clin Infect Dis. 2020 Aug 6
- 366 14. L'Huillier AG, Torriani G, Pigny F, Kaiser L, Eckerle I. Culture-Competent SARS-CoV-2 in Nasopharynx of 367 Symptomatic Neonates, Children, and Adolescents. Emerg Infect Dis. 2020 Oct;26(10):2494–7.
- 368 15. Wölfel R, Corman VM, Guggemos W, Seilmaier M, Zange S, Müller MA, et al. Virological assessment of 369 hospitalized patients with COVID-2019. Nature. 2020 May;581(7809):465-9.
- 370 16. Kampen JJA van, Vijver DAMC van de, Fraaij PLA, Haagmans BL, Lamers MM, Okba N, et al. Shedding of 371 infectious virus in hospitalized patients with coronavirus disease-2019 (COVID-19): duration and key 372 determinants. medRxiv. 2020 Jun 9;2020.06.08.20125310.

medRxiv preprint doi: https://doi.org/10.1101/2020.11.20.20235341; this version posted November 23, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

- Vetter P, Eberhardt CS, Meyer B, Martinez Murillo PA, Torriani G, Pigny F, et al. Daily Viral Kinetics and
 Innate and Adaptive Immune Response Assessment in COVID-19: a Case Series. Spiropoulou CF, editor.
 mSphere. 2020 Dec 23;5(6):e00827-20.
- Krueger LJ, Gaeddert M, Koeppel L, Bruemmer L, Gottschalk C, Miranda IB, et al. Evaluation of the
 accuracy, ease of use and limit of detection of novel, rapid, antigen-detecting point-of-care diagnostics
 for SARS-CoV-2. medRxiv. 2020 Oct 4;2020.10.01.20203836.
- Second Straight S
- 382 20. Gupta A, Khurana S, Das R, Srigyan D, Singh A, Mittal A, et al. Rapid chromatographic immunoassay based evaluation of COVID-19: A cross-sectional, diagnostic test accuracy study & its implications for
 COVID-19 management in India. The Indian journal of medical research. 2020 Oct 31;Online ahead of
 print.
- FIND. FIND Evaluation of SD Biosensor, Inc. STANDARD TM Q COVID-19 Ag FIA External Report. 2020.
 FIND; 2020.
- Chaimayo C, Kaewnaphan B, Tanlieng N, Athipanyasilp N, Sirijatuphat R, Chayakulkeeree M, et al. Rapid
 SARS-CoV-2 antigen detection assay in comparison with real-time RT-PCR assay for laboratory diagnosis
 of COVID-19 in Thailand. Virology Journal. 2020 Nov 13;17(1):177.
- Nalumansi A, Lutalo T, Kayiwa J, Watera C, Balinandi S, Kiconco J, et al. Field Evaluation of the
 Performance of a SARS-CoV-2 Antigen Rapid Diagnostic Test in Uganda using Nasopharyngeal Samples.
 International Journal of Infectious Diseases. 2020 Oct 30;Epub ahead of print.
- Gremmels H, Winkel BMF, Schuurman R, Rosingh A, Rigter NAM, Rodriguez O, et al. Real-life validation of
 the Panbio COVID-19 Antigen Rapid Test (Abbott) in community-dwelling subjects with symptoms of
 potential SARS-CoV-2 infection. medRxiv. 2020 Jan 1;2020.10.16.20214189.
- Alemany A, Baro B, Ouchi D, Ubals M, Corbacho-Monné M, Vergara-Alert J, et al. Analytical and Clinical
 Performance of the Panbio COVID-19 Antigen-Detecting Rapid Diagnostic Test. medRxiv. 2020 Nov
 3;2020.10.30.20223198.
- Albert E, Torres I, Bueno F, Huntley D, Molla E, Fernández-Fuentes MÁ, et al. Field evaluation of a rapid
 antigen test (PanbioTM COVID-19 Ag Rapid Test Device) for the diagnosis of COVID-19 in primary
 healthcare centers. medRxiv. 2020 Oct 20;2020.10.16.20213850.
- Linares M, Pérez-Tanoira R, Carrero A, Romanyk J, Pérez-García F, Gómez-Herruz P, et al. Panbio antigen
 rapid test is reliable to diagnose SARS-CoV-2 infection in the first 7 days after the onset of symptoms.
 Journal of Clinical Virology. 2020 Oct 16;104659.
- 406
 407
 407
 408
 408
 408
 408
 408
 408
 408
 408
 408
 408
 408
 408
 408
 408
 408
 408
 408
 408
 408
 408
 408
 408
 408
 408
 408
 408
 408
 408
 408
 408
 408
 408
 408
 408
 408
 408
 408
 408
 408
 408
 408
 408
 408
 408
 408
 408
 408
 408
 408
 408
 408
 408
 408
 408
 408
 408
 408
 408
 408
 408
 408
 408
 408
 408
 408
 408
 408
 408
 408
 408
 408
 408
 408
 408
 408
 408
 408
 408
 408
 408
 408
 408
 408
 408
 408
 408
 408
 408
 408
 408
 408
 408
 408
 408
 408
 408
 408
 408
 408
 408
 408
 408
 408
 408
 408
 408
 408
 408
 408
 408
 408
 408
 408
 408
 408
 408
 408
 408
 408
 408
 408
 408
 408
 408
 408
 408
 408
 408
 408
 408
 408
 408
 408
 408
 408
 408
 408
 408
 408
 408
 408
 408
 408
 408
 408
 408
 408
 408
 408
 408
 408
 408
 408
 408
- 40929.Larremore DB, Wilder B, Lester E, Shehata S, Burke JM, Hay JA, et al. Test sensitivity is secondary to410frequency and turnaround time for COVID-19 surveillance. medRxiv [Internet]. 2020 Sep 8 [cited 2020411Nov 18]; Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7325181/
- Lindner AK, Nikolai O, Kausch F, Wintel M, Hommes F, Gertler M, et al. Head-to-head comparison of
 SARS-CoV-2 antigen-detecting rapid test with self-collected anterior nasal swab versus professional collected nasopharyngeal swab. medRxiv. 2020 Oct 27;2020.10.26.20219600.
- 415

416 Tables

417 Table 1.

| Characteristics | Standard Q (n=529) | Panbio (n=535) | Combined (n=1064) | p-value |
|-----------------------------------|-----------------------|-------------------|----------------------|---------|
| Mean age (±SD, median) | 34.9 (±10.9, 33) | 38.5 (±13.6, 36) | 36.7 (±12.5, 34) | < 0.001 |
| Sex distribution, n (%) | | | | 0.966 |
| Women | 285 (53.9) | 287 (53.6) | 572 (53.8) | |
| Men | 244 (46.1) | 248 (46.4) | 492 (46.2) | |
| Mean DPOS to RT-PCR (±SD, median) | 2.9 (±1.5, 3) | 2.6 (±2.0, 2) | 2.7 (±1.9, 2) | 0.0125 |
| Result of RT-PCR, n (%) | | | | <0.001 |
| Negative | 338 (63.9) | 411 (76.8) | 749 (70.4) | |
| Positive | 191 (36.1) | 124 (23.2) | 315 (29.6) | |
| Mean Ct (±SD, median) (n=315) | 22.6 (±4.9, 21.8) | 22.4 (±5.4, 21.0) | 22.5 (±5.1, 21.5) | 0.450 |

418 Table 1. Characteristics of the study population. SD, standard deviation; RT-PCR, reverse transcription

419 polymerase chain reaction; DPOS, days post symptom onset; Ct, cycle threshold

420

421 Table 2.

| Characteristics | Standard Q | Panbio | Combined |
|--------------------------------------|------------------|------------------|------------------|
| SN, % (95%CI) | 89.0 (83.7-93.1) | 85.5 (78.0-91.2) | 87.6 (83.5-91.0) |
| SP, % (95%CI) | 99.7 (98.4-100) | 100 (99.1-100) | 99.9 (99.3-100) |
| Positive predictive value, % (95%CI) | 99.4 (96.8-100) | 100 (96.6-100) | 99.6 (98.0-100) |
| Negative predictive value, % (95%CI) | 94.1 (91.2-96.3) | 95.8 (93.4-97.5) | 95 (93.3-96.5) |

422 Table 2. Overall SN, SP, positive and negative predictive value of Standard Q and Panbio SARS-CoV-2 Ag-RDT.

423 Positivity rate at the time of study for Standard Q was 36.1% and at the time of study for Panbio was 23.2%.

424 **Figures**



425

426 Figure 1. Ct values, viral load and Ag-RDT results for RT-PCR-positive individuals tested with Standard Q (n= 191) 427 and Panbio (n=124). Horizontal bars represent median and standard deviation. Dotted line: Ct value of 26.7 or 428 1E6 SARS-CoV-2 RNA copy numbers/mL.

429



431 Figure 2. Ct values, viral load, days post symptom onset and Ag-RDT results for 190 patients tested with Standard 432 Q (A) and 116 patients tested with Panbio (B) for which information on day of symptom onset was available. 433 Dotted line: Ct value of 26.7 or 1E6 SARS-CoV-2 RNA copy numbers/mL.

medRxiv preprint doi: https://doi.org/10.1101/2020.11.20.20235341; this version posted November 23, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .



Figure 3. A. Combined SN of the two Ag-RDTs according to Ct-values of the RT-PCR. B. Combined SN of the two
Ag-RDTs according to subgroups of Ct-values of the RT-PCR. Ct values correspond to the following SARS-CoV-2
RNA copy numbers/mL: Ct 20: 1.0E8; Ct 25: 3.2E6; Ct 26.7: 1E6; Ct 30: 1.0E5, Ct 35: 3.2E3.

438

439



Figure 4. A. Combined SN of the two Ag-RDTs according to days post symptom onset. Number of patients per
category: Day 0, n= 17; day 1, n=53, day 2-3, n=135; day 4-5, n=58; day 6-7, n=14; > 7 days, n= 9). B. Combined
SN of the two Ag-RDTs according to symptoms F, fever/chills; C, cough, A, anosmia/ageusia (loss of smell or
taste), Us, unspecific symptoms (all other symptoms excluding fever/chills, cough and anosmia/angeusia).
Number of patients per category: F, n= 172; F and C, n= 97; F and A or C, n=111; A or C, n= 202; A, n= 79; Us,
n=42.